Randomized Trial Comparing Colesevelam vs. Ezetimibe
Randomized Trial Comparing Colesevelam vs. Ezetimibe
NCT ID: NCT02682680 Phase: PHASE4 Status: COMPLETED Enrollment: 200 Completion: 2017-05-25
Conditions
Type 2 Diabetes Mellitus
Interventions
Colesevelam, Ezetimibe
Summary
A 24-week, randomized, open-label study investigating the efficacy, safety and tolerability of colesevelam 3.75 g daily compared to ezetimibe 10 mg daily, as an add-on to baseline statin therapy in patients with type 2 diabetes mellitus (T2DM) who are not at target for glycated hemoglobin (HbA1c) (> 7.0%) and low-density lipoprotein (LDL) cholesterol (> 2.0 mmol/L).
Primary Outcome
Proportion of subjects who achieve target HbA1c and LDL cholesterol